Navigation Links
Progenics Announces Positive Results in Clinical Trial of Novel HIV,Therapy

TARRYTOWN, N.Y.--(BUSINESS WIRE)--May 1, 2007 - Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) today announced positive results from the first clinical trial of its investigational drug, PRO 140, in individuals infected with the human immunodeficiency virus (HIV), the causative agent of AIDS. Patients receiving a single 5.0 mg/kg dose of PRO 140 achieved an average maximum decrease of viral concentrations in the blood of 98.5% (1.83 log10), with individual reductions ranging up to 99.7% (2.5 log10). In these patients, reductions in viral load of greater than 90% (1.0 log10) on average persisted for two to three weeks after dosing. In addition, PRO 140 was generally well tolerated in this phase 1b proof-of-concept study. PRO 140 was granted Fast Track status from the U.S. Food and Drug Administration (FDA), and Progenics plans to initiate additional clinical testing in the second half of 2007.

"This study establishes clear proof of concept for PRO 140 as a potent antiretroviral agent with extended activity following a single dose," said Scott M. Hammer, M.D., Chief, Division of Infectious Diseases and Harold C. Neu Professor of Medicine, Columbia University College of Physicians and Surgeons, New York City. "The primary goal of HIV therapy is to provide maximal and durable suppression of viral replication. Based on this study, PRO 140 has the potential to add to the armamentarium of drugs that can help achieve this goal in patients living with HIV, including those whose treatment options are limited by drug resistance."

PRO 140 is a humanized monoclonal antibody that binds CCR5, the principal portal used by HIV to enter cells. Viral-entry inhibition using a long-lived antibody represents a promising novel approach to treating HIV infection. Unlike currently available antiretroviral drugs, PRO 140 does not target the virus, but rather binds to the CCR5 receptor on healthy immune system cells and thereby pr
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Progenics and Wyeth Announce Positive Results from Three-Month Clinical-Extension Study of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:7/30/2014)... July 30, 2014  Lightlake Therapeutics Inc. ("Lightlake") ... based on its expertise in opioid antagonists, announced ... from a prominent international research and development foundation. ... promoting innovative research-based initiatives, including those addressing health ... for the delivery of naloxone that could widely ...
(Date:7/30/2014)...  Hospira, Inc. (NYSE: HSP ), ... infusion technologies, today reported results for the second ... the quarter were $1.1 billion and adjusted* diluted ... specified items as described later in this press ... Generally Accepted Accounting Principles (GAAP) basis, second-quarter 2014 ...
(Date:7/30/2014)... ANTONIO , July 30, 2014   ... company focused on innovating lifesaving devices and methods ... $4.5 million in Series A financing, which was ... Proceeds from the deal will allow Bluegrass Vascular ... Access Catheter System, enhance manufacturing capabilities, and proceed ...
Breaking Medicine Technology:Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 2Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 3Hospira Reports Second-Quarter 2014 Results 2Hospira Reports Second-Quarter 2014 Results 3Hospira Reports Second-Quarter 2014 Results 4Hospira Reports Second-Quarter 2014 Results 5Hospira Reports Second-Quarter 2014 Results 6Hospira Reports Second-Quarter 2014 Results 7Hospira Reports Second-Quarter 2014 Results 8Hospira Reports Second-Quarter 2014 Results 9Hospira Reports Second-Quarter 2014 Results 10Hospira Reports Second-Quarter 2014 Results 11Hospira Reports Second-Quarter 2014 Results 12Hospira Reports Second-Quarter 2014 Results 13Hospira Reports Second-Quarter 2014 Results 14Hospira Reports Second-Quarter 2014 Results 15Hospira Reports Second-Quarter 2014 Results 16Hospira Reports Second-Quarter 2014 Results 17Hospira Reports Second-Quarter 2014 Results 18Hospira Reports Second-Quarter 2014 Results 19Hospira Reports Second-Quarter 2014 Results 20Hospira Reports Second-Quarter 2014 Results 21Hospira Reports Second-Quarter 2014 Results 22Hospira Reports Second-Quarter 2014 Results 23Hospira Reports Second-Quarter 2014 Results 24Hospira Reports Second-Quarter 2014 Results 25Hospira Reports Second-Quarter 2014 Results 26Hospira Reports Second-Quarter 2014 Results 27Hospira Reports Second-Quarter 2014 Results 28Hospira Reports Second-Quarter 2014 Results 29Hospira Reports Second-Quarter 2014 Results 30Hospira Reports Second-Quarter 2014 Results 31Bluegrass Vascular Technologies Raises $4.5M Series A Financing Led By Targeted Technology Funds 2
(Date:7/30/2014)... 2014 Nationally recognized leader in nursing ... since September 2013 has served as president of the ... dean of the College of Nursing at University of ... leadership of the NLN, as the nation's premier voice ... nursing and research institutions in the country. , ...
(Date:7/30/2014)... 2014 Within weeks freshman will begin to pour ... hopes this will be a time of growth and the start ... pause; it may not be as easy as it looks. Some ... switch their major at least once and many will switch two ... the costs are exacerbated when switching in the later years of ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 Throughout the ... patients with free oral cancer screenings. Using a new ... work to detect the disease in its early stages. ... tongue, cheek, mouth, sinuses, throat and other areas in ... Institute’s Surveillance, Epidemiology, and Ends Results (SEER) program, 30 ...
(Date:7/30/2014)... 2014 Serial entrepreneur, Paul Mata, spent the ... However, like most people, in 2008 he suffered extreme financial ... better way, Paul carefully studied the difference between people who ... not. Based on the knowledge he acquired, he was able ... life and health, but also grow his clients' personal and ...
(Date:7/30/2014)... Thompson HealthDay Reporter WEDNESDAY, ... are more likely to develop dementia, but researchers have been ... the two. Specifically, they haven,t been able to figure ... depression help bring on dementia, or does dementia cause people ... 30 in the journal Neurology sheds more light ...
Breaking Medicine News(10 mins):Health News:National League for Nursing Congratulates League President Marsha Adams on Appointment as Dean of College of Nursing at University of Alabama-Huntsville 2Health News:National League for Nursing Congratulates League President Marsha Adams on Appointment as Dean of College of Nursing at University of Alabama-Huntsville 3Health News:Advice to College Freshman from Author Garrett Miller 2Health News:Advice to College Freshman from Author Garrett Miller 3Health News:Restore Dental Offers Complimentary Oral Cancer Screenings in August 2Health News:Paul Mata Kicks off 3-day Wealth Bootcamp on September 11th 2Health News:Paul Mata Kicks off 3-day Wealth Bootcamp on September 11th 3Health News:Scientists Shed Light on Link Between Depression, Dementia 2Health News:Scientists Shed Light on Link Between Depression, Dementia 3
... ... is happy to provide his patients with Invisalign clear aligners, a new technology that ... make getting straight teeth easier than ever before. , ... Torrance, California (PRWEB) April 29, 2010 -- ...
... cancers could soon allow researchers to identify groups of ... with angiogenesis-inhibitor drugs, a Spanish team reports. Dr ... reports new findings from an analysis of 135 lung ... Carlos Camps, evaluated the expression of 8 different genes ...
... (found in some foods) may help alleviate the severity ... new research study appearing in the May 2010 print ... ( http://www.jleukbio.org ), differing intestinal bacteria in celiac patients ... manipulating the intestinal microbiota with dietary strategies such as ...
... ... FDA Criticisms—Form 483 Letters—for Temperature, Humidity and other Controlled Environments” , ... (Vocus) April 29, ... Letters—for Temperature, Humidity and other Controlled Environments” is now available from Veriteq ...
... risky but can be beneficial, researchers say , THURSDAY, ... better if they undergo deep brain stimulation surgery in ... One year after having the procedure, patients who underwent ... ability to get around and engage in routine daily ...
... ... saying that seems to ring true according to husbands whose wives have had plastic surgery. ... a look at the transformative journey from the husband,s perspective. , ... Newport Beach, Calif (Vocus) April 29, 2010 -- Dr. ...
Cached Medicine News:Health News:Invisalign Clear Aligners Available at Blue Sky Family Dental by Torrance Dentist, Dr. Robert Mondavi 2Health News:Invisalign Clear Aligners Available at Blue Sky Family Dental by Torrance Dentist, Dr. Robert Mondavi 3Health News:Spanish gene expression data promise targeting of anti-angiogenesis treatment 2Health News:Gut bacteria offer new insights -- and hope -- for people with celiac disease 2Health News:Guide for US FDA-Regulated Organizations Now Available 2Health News:Guide for US FDA-Regulated Organizations Now Available 3Health News:Adding Surgery to Meds May Improve Life With Parkinson's 2Health News:Cruise Plastic Surgery Looks at Mommy Makeovers from the Husband's Perspective and Offers Tips 2Health News:Cruise Plastic Surgery Looks at Mommy Makeovers from the Husband's Perspective and Offers Tips 3Health News:Cruise Plastic Surgery Looks at Mommy Makeovers from the Husband's Perspective and Offers Tips 4
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: